Email
Print
Kinase Inhibitors Market is estimated to reach $91.3 billion by 2028, growing at a CAGR of 7.1% over the forecast period 2023-2028. Chronic
myeloid leukaemia (CML) is a cancer of the white blood cells that are defined by
the accumulation of myeloid cells in the blood and the accelerated and
uncontrolled proliferation of these cells in the bone marrow. The incidence of
chronic myeloid leukaemia (CML), a myeloproliferative neoplasm, is 1-2
occurrences per 100,000 adult patients. According to the American Cancer
Society, there will be around 8,860 new cases of chronic myeloid leukemia
(CML) diagnosed in 2022 and there will also be approximately 1,220 deaths from
CML. Tyrosine-kinase inhibitors (TKIs), which have significantly increased
long-term survival rates, are the main targeted medications used to treat CML. According
to reports, these medications, as opposed to earlier chemotherapy medications,
have transformed the way this disease is treated by enabling the majority of
patients to live healthy lives. Therefore, it is anticipated that the market
for tyrosine kinase inhibitor therapy will develop along with the prevalence of
CML.
Kinase Inhibitors Market
– Drivers
Innovation and Advancement of Technology to Expand the Market.
The market
for kinase inhibitors is changing owing to the innovations like artificial
intelligence. For instance, the American biotechnology start-up Insilico
Medicine unveiled a deep learning approach that uses Discoid in Domain Receptor
1 (DDR 1) kinase inhibitors to find possible fibrosis treatments. Receptor tyrosine kinases and
non-receptor tyrosine kinases are two types of tyrosine kinases. Additionally,
a number of healthcare organizations are utilizing generative adversarial
networks (GANs) to generate unique molecular structures with predetermined
features. Similarly to this, deep learning is enabling businesses to quickly
identify effective DDR1 kinase inhibitors. Furthermore, the use of plasma-based
assays is enabling greater detection of gene mutations in individuals who
reject tissue biopsy. As a result of these scientific advancements, the
Collection of Somatic Mutations in Cancer database now contains descriptions of
more than 600 epidermal growth factor receptor variants. Thus, the market is
growing as a result of all these innovations.
For More Queries About "Kinase Inhibitors Market" @ https://www.industryarc.com/support.php?id=15928
Increasing Usage for Kinase Inhibitors to Boost the Market Growth.
The progression of many diseases, including cancer,
rheumatoid arthritis, Alzheimer's disease and viral infections, is facilitated
by a range of therapeutic targets known as kinases. Virus-specific targets that
are encoded by individual viruses make up the majority of authorized antiviral
medicines. These inhibitors are specific drugs that can lead to the emergence
of resistance. For the progression of the life cycle, viruses are dependent on
host cellular proteins, particularly kinases. The enzyme family has emerged as
one of the most significant pharmacological targets in the 21st century as a
result of the dysregulation of protein kinase activity in numerous illnesses,
including cancer. About 20 different protein kinases are the target of 68 Food
and Drug Administration (FDA) approved medicinal medicines, six of which were
approved in 2021. Thus, a key therapeutic strategy for finding broad-spectrum
antiviral drugs is to target kinases, which further enhances market growth.
R&D
Investment:
In July 2021, Ocular Therapeutix Inc.
administered the first dosage to the patient in the United States Phase 1
clinical study of OTX-TKI (axitinib intravitreal implant) to treat wet
age-related macular degeneration.
Major
Players in this Market:
The major companies in the pharmaceutical packaging industry include Pfizer, Novartis AG, Roche, AstraZeneca, Eisai Co. Ltd., Bristol-Myers Squibb, Bayer AG, Johnson & Johnson, GlaxoSmithKline, Hutch Med, Ocular Therapeutix Inc. and Others.